Éric Legouffe

4.9k total citations · 1 hit paper
49 papers, 3.2k citations indexed

About

Éric Legouffe is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Éric Legouffe has authored 49 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 16 papers in Molecular Biology and 15 papers in Hematology. Recurrent topics in Éric Legouffe's work include Multiple Myeloma Research and Treatments (12 papers), Renal cell carcinoma treatment (7 papers) and Lymphoma Diagnosis and Treatment (7 papers). Éric Legouffe is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Renal cell carcinoma treatment (7 papers) and Lymphoma Diagnosis and Treatment (7 papers). Éric Legouffe collaborates with scholars based in France, Switzerland and United Kingdom. Éric Legouffe's co-authors include Bernard Klein, Karin Tarte, Éric Jourdan, Jérôme Moreaux, Thierry Rème, Jean‐François Rossi, Jean François Rossi, John De Vos, Claire Cropet and Philippe Quittet and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Éric Legouffe

49 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

2012 539 citations Thomas Bachelot, C. Bourgier et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Éric Legouffe France	24	1.3k	1.3k	1.1k	848	707	49	3.2k
Peter Langmuir United States	30	1.3k 1.0×	1.8k 1.4×	555 0.5×	1.6k 1.9×	888 1.3×	56	4.7k
Alison M. Schram United States	25	1.1k 0.8×	1.1k 0.8×	658 0.6×	862 1.0×	465 0.7×	100	2.9k
Thomas A. Puchalski United States	24	905 0.7×	1.5k 1.2×	362 0.3×	834 1.0×	789 1.1×	51	2.8k
Yusri Elsayed United States	22	1.1k 0.8×	1.1k 0.9×	414 0.4×	606 0.7×	422 0.6×	51	2.4k
Gerold Meinhardt United States	27	1.0k 0.8×	1.3k 1.0×	356 0.3×	725 0.9×	359 0.5×	58	4.8k
Patrizia Mancuso Italy	33	2.6k 2.0×	2.3k 1.8×	377 0.4×	618 0.7×	682 1.0×	80	4.4k
Christian Scheffold United States	25	900 0.7×	1.0k 0.8×	346 0.3×	1.0k 1.2×	536 0.8×	75	2.3k
Dirk Behringer Germany	27	630 0.5×	1.1k 0.8×	633 0.6×	388 0.5×	424 0.6×	69	2.2k
Wael A. Harb United States	23	923 0.7×	1.4k 1.1×	265 0.2×	759 0.9×	259 0.4×	118	2.5k
Morten Mau‐Sørensen Denmark	28	1.1k 0.8×	1.2k 0.9×	258 0.2×	527 0.6×	276 0.4×	130	2.7k

Countries citing papers authored by Éric Legouffe

Since Specialization

Citations

This map shows the geographic impact of Éric Legouffe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Éric Legouffe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Éric Legouffe more than expected).

Fields of papers citing papers by Éric Legouffe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Éric Legouffe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Éric Legouffe. The network helps show where Éric Legouffe may publish in the future.

Co-authorship network of co-authors of Éric Legouffe

This figure shows the co-authorship network connecting the top 25 collaborators of Éric Legouffe. A scholar is included among the top collaborators of Éric Legouffe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Éric Legouffe. Éric Legouffe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vendrell, Julie A., Isabelle Solassol, Simon Cabello‐Aguilar, et al.. (2023). Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences. 24(18). 14181–14181. 4 indexed citations

Firmin, Nelly, Célia Touraine, Angélique Chapelle, et al.. (2021). A Phase II Multicenter Trial on High-Dose Vitamin D Supplementation for the Correction of Vitamin D Insufficiency in Patients with Breast Cancer Receiving Adjuvant Chemotherapy. Nutrients. 13(12). 4429–4429. 5 indexed citations

Verger, Emmanuelle, Bruno Cassinat, Aurélie Chauveau, et al.. (2015). Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations. Blood. 126(24). 2585–2591. 109 indexed citations

Treilleux, Isabelle, Mónica Arnedos, Claire Cropet, et al.. (2014). Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. Annals of Oncology. 26(1). 120–125. 68 indexed citations

Bachelot, Thomas, C. Bourgier, Claire Cropet, et al.. (2012). Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study. Journal of Clinical Oncology. 30(22). 2718–2724. 539 indexed citations breakdown →

Bourgier, C., Claire Cropet, J P Guastalla, et al.. (2010). Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).. Cancer Research. 70(24_Supplement). S1–6. 45 indexed citations

Escudier, B., Sylvie Négrier, Gwénaëlle Gravis, et al.. (2010). Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial.. Journal of Clinical Oncology. 28(15_suppl). 4516–4516. 38 indexed citations

Moreaux, Jérôme, Dirk Hose, Thierry Rème, et al.. (2006). CD200 is a new prognostic factor in multiple myeloma. Blood. 108(13). 4194–4197. 191 indexed citations

Quittet, Philippe, Patrice Céballos, Lu Zhang, et al.. (2006). Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients. Bone Marrow Transplantation. 38(4). 275–284. 10 indexed citations

10.

Fegueux, Nathalie, Lu Zhang, Éric Legouffe, et al.. (2005). Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplantation. 36(9). 771–779. 44 indexed citations

11.

Milpied, Nöel, T. Lamy, Philippe Casassus, et al.. (2004). Front-Line High-Dose Chemotherapy (HDT) Combined with Rituximab for Adults with Aggressive Large B-Cell Lymphoma (DLBCL) : Goelams 074 Trial.. Blood. 104(11). 902–902. 2 indexed citations

12.

Bessis, D., B. Guillot, Éric Legouffe, & Jean‐Jacques Guilhou. (2004). Gemcitabine-associated scleroderma-like changes of the lower extremities. Journal of the American Academy of Dermatology. 51(2). 73–76. 48 indexed citations

13.

Moreaux, Jérôme, Éric Legouffe, Éric Jourdan, et al.. (2003). BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 103(8). 3148–3157. 429 indexed citations

14.

Klein, Bernard, Karin Tarte, Michel Jourdan, et al.. (2003). Survival and Proliferation Factors of Normal and Malignant Plasma Cells. International Journal of Hematology. 78(2). 106–113. 175 indexed citations

15.

Tarte, Karin, John De Vos, Thomas Thykjær, et al.. (2002). Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood. 100(4). 1113–1122. 117 indexed citations

16.

Godeau, Bertrand, Sylvie Chevret, Bruno Varet, et al.. (2002). Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. The Lancet. 359(9300). 23–29. 189 indexed citations

17.

Legouffe, Éric, Carmen Rodrı́guez, Bruno Richard, et al.. (1998). C-Reactive Protein Serum Level is a Valuable and Simple Prognostic Marker in Non Hodgkin's Lymphoma. Leukemia & lymphoma. 31(3-4). 351–357. 101 indexed citations

18.

Jourdan, Michel, Éric Legouffe, Mira Horváthová, et al.. (1998). The myeloma cell antigen syndecan‐1 is lost by apoptotic myeloma cells. British Journal of Haematology. 100(4). 637–646. 106 indexed citations

19.

Brochier, J, Éric Legouffe, Jean‐Pierre Liautard, et al.. (1995). Immunomodulating IL-6 activity by murine monoclonal antibodies. International Journal of Immunopharmacology. 17(1). 41–48. 12 indexed citations

20.

Legouffe, Éric, Jean‐François Rossi, Jean-Philippe Laporte, et al.. (1995). Treatment of Waldenstrom's Macroglobulinemia with Very Low Doses of Alpah Interferon. Leukemia & lymphoma. 19(3-4). 337–342. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact